HealthKey
HealthKey scans your EHR daily and emails you clinical trial patients who match your protocol's eligibility criteria.
HealthKey makes the strongest case in patient identification right now because the incentives line up — you pay per enrolled patient, not per seat, and the documented outcomes are specific enough to sanity-check (12,004 screened for 23 eligible; 11,041 patients across four clinics to a first enrollment in 25 days). Against Deep 6 AI or Mendel, the pitch is alignment: no enrollment, no payment. It is sales-led with onboarding capped at 20 new sites per quarter, so this is not same-day adoption — and the waived implementation, protocol setup, and premium support offer is valid only through July 31, 2026. If enrollment speed is your bottleneck in obesity, epilepsy, or cardiovascular, it's
Verified 1d ago · liveness 60/100 · cite: rightaichoice.com/tools/healthkey
- Clinical research sites with enrollment bottlenecks and no appetite for upfront license fees
- CROs running multi-site trials who need rapid, evidence-backed patient identification
- Sponsors with enrollment-constrained protocols in obesity, epilepsy, or cardiovascular
- Sites burned by expensive patient-ID tools who want pay-per-enrollment risk
- Individual clinicians or solo practices outside clinical research
- Patients looking for direct trial enrollment — there's no consumer portal
- Sites with very small EHRs or few patients where prescreening adds little
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip HealthKey if your study isn't enrollment-constrained, your site has a small EHR with too few patients for prescreening to add value, or you need to be onboarding this week — new sites are capped at 20 per quarter.
You pay a success fee for every enrolled patient, so a trial that enrolls faster than forecast costs proportionally more than a fixed license would.
HealthKey's success-fee model sits differently from seat- or license-priced patient-ID tools: you pay per enrolled patient, so cost tracks enrollment rather than headcount. Multi-site groups screening millions of records get the most leverage from that structure, while small sites with a handful of eligible patients see limited benefit. The current offer waiving $22,500 in implementation, protocol setup, and support fees makes the first studies materially cheaper through July 31, 2026.
In short
HealthKey — HealthKey scans your EHR daily and emails you clinical trial patients who match your protocol's eligibility criteria. Best for Clinical research sites with enrollment bottlenecks and no appetite for upfront license fees, CROs running multi-site trials who need rapid, evidence-backed patient identification, Sponsors with enrollment-constrained protocols in obesity, epilepsy, or cardiovascular. Contact Sales pricing.
What's new in HealthKey
Checked yesterdayAcross the latest 5 updates: 5 news mentions.
How Flourish Research Screened 4,269 Hypertension Patients and 364,607 medical records for a Global Cardiovascular Trial
On the Alnylam ZENITH trial, Flourish Research screened 4,269 patients against 24 criteria, saving an estimated 1,280 manual chart-review hours.
How Flourish Research Screened 12,004 Patients Across 6 Sites for a Phase 3 Obesity Trial Targeting GLP-1 Add-On Therapy
For Eli Lilly's ENLIGHTEN-6, 12,004 patients and 4.6M records were screened across six sites, identifying 23 eligible patients with verification of stable GLP-1 therapy and BMI thresholds.
How Flourish Research screened 11,041 patients across 4 clinics and enrolled for a novel obesity biologic in 25 days
4.2M records processed across four EHRs, 323 eligible patients identified, and a first enrollment in 25 days for a first-in-class obesity biologic.
How Access CCT Went from Two Enrolled Patients to a Pipeline of 39 on a Trial a Year Behind Schedule
On a Phase 2/3 epilepsy trial, 996,044 records were processed and 39 eligible patients found from 5,608 screened — including one patient missed by another platform.
"Will Not Be an Easy Protocol." How Tekton Went From a 42-Criteria Protocol to 14 Qualified Patients in 11 Days
On UCB's bimekizumab protocol, HealthKey encoded 42 criteria across two disease cohorts and identified 14 qualified patients in 11 days.
What people actually say about HealthKey — is it worth it?
We scanned public community sources for HealthKey on Aug 20, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Our own analysis of that scan says the posts were off-subject. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.
Viability Score
How well maintained and how widely used is HealthKey? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- AI-powered patient prescreening against trial inclusion and exclusion criteria
- Daily EHR scans to surface newly eligible patients
- HIPAA-compliant EHR integration and data processing
- Custom encoding of complex multi-criteria protocols (42-criteria protocols handled)
- Match results presented with supporting evidence from patient records
- Ready-to-enroll candidate list delivered to dashboard and email
- Success-fee pricing charged per enrolled patient
- Free implementation (valued at $15,000) through July 31, 2026
- Free protocol setup for 5 trials (valued at $5,000)
- Free premium support (valued at $2,500)
- One-week onboarding to first qualified candidates
- Supports multi-site and multi-EHR trials (four EHRs in a documented case)
- Handles obesity, epilepsy, cardiovascular, urology, and oncology protocols
- Scales to millions of patient records and thousands of screened patients
- Email delivery of daily eligible-patient lists
About HealthKey
HealthKey is AI-powered patient identification software for clinical trial teams. You connect it to your EHR in a HIPAA-compliant way, encode a protocol's inclusion and exclusion criteria, and the platform scans patient records on a daily cadence to surface candidates your coordinators would otherwise miss. Matches arrive with the underlying chart evidence, so your research team can confirm eligibility without re-reading entire records, and the ready-to-enroll list lands in both a dashboard and your inbox. Documented results are specific: for Eli Lilly's ENLIGHTEN-6 Phase 3 obesity trial, a site screened 12,004 patients across 4.6M records and landed 23 eligible with verification of stable GLP-1 therapy and BMI thresholds. A first-in-class obesity biologic screened 11,041 patients across four clinics (4.2M records, four EHRs) for 323 eligible and a first enrollment in 25 days. On UCB's bimekizumab protocol, 42 criteria across two disease cohorts yielded 14 qualified patients in 11 days. Flourish Research screened 4,269 patients against 24 criteria for the Alnylam ZENITH cardiovascular trial, saving an estimated 1,280 manual chart-review hours. Access CCT went from two enrolled patients to a pipeline of 39 on a Phase 2/3 epilepsy trial, processing 996,044 records and finding one patient missed by another platform. HealthKey charges success fees per enrolled patient rather than a large upfront license, with a current offer through July 31, 2026 waiving implementation ($15,000), protocol setup for five trials ($5,000), and premium support ($2,500). New-site onboarding is capped at 20 sites per quarter. It is built for research sites, CROs, and sponsors running enrollment-constrained studies in obesity, epilepsy, cardiovascular, urology, and oncology.
Behind the Verdict
HealthKey's pitch is narrow and credible: it does not try to be a trial management system or an EDC. It connects to your EHR, encodes eligibility criteria, scans records on a daily cadence, and hands your coordinators a matched list with chart evidence attached. That single workflow is where the money is for most sites, because manual chart review is the slowest and most expensive part of enrollment. The case-study record is the reason to take this seriously. Eli Lilly's ENLIGHTEN-6 obesity trial: 12,004 patients and 4.6M records screened across six sites, 23 eligible, with verification of stable GLP-1 therapy and BMI thresholds. A first-in-class obesity biologic: 11,041 patients across four clinics and four separate EHRs, 4.2M records processed, 323 eligible, first enrollment in 25 days. UCB's bimekizumab protocol: 42 criteria across two disease cohorts, 14 qualified patients in 11 days. Flourish Research's run on the Alnylam ZENITH cardiovascular trial screened 4,269 patients against 24 criteria and saved an estimated 1,280 manual chart-review hours. Access CCT's Phase 2/3 epilepsy trial went from two enrolled patients to a pipeline of 39, processing 996,044 records — and surfaced one patient another platform missed. Those are unusually concrete numbers for this category, and multi-EHR coverage is the detail that matters most to multi-site groups. The commercial model is the other differentiator. Success fees per enrolled patient rather than a large upfront license shifts risk onto HealthKey. The current offer — implementation ($15,000), protocol setup for five trials ($5,000), and premium support ($2,500) waived through July 31, 2026 — lowers the cost of a first study considerably. The flip side is onboarding capacity: new sites are capped at 20 per quarter, so a trial with an urgent start date may not get in this quarter. Where it fits: research sites with an enrollment bottleneck and no appetite for upfront license fees, CROs running multi-site trials who need rapid evidence-backed identification, sponsors with enrollment-constrained protocols in obesity, epilepsy, or cardiovascular, and any team whose coordinators are buried in manual chart review. Where it does not: individual clinicians outside clinical research, solo practices with small EHRs where prescreening adds little, and anyone who needs to be live immediately rather than in a queue.
Researching HealthKey? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas HealthKey actually fits — and what changes day-one when you adopt it.
Connect HealthKey to the site EHR, upload a Phase 3 obesity protocol's inclusion and exclusion criteria, and let the platform scan records daily.
Outcome: A dashboard and email list of matched patients with chart evidence attached, so coordinators screen for eligibility instead of reading whole records — the same pattern that screened 12,004 patients across six sites in the ENLIGHTEN-6 case study.
Encode 24 protocol criteria and run prescreening across four clinic locations and their separate EHRs.
Outcome: 4,269 patients screened against 24 criteria with an estimated 1,280 manual chart-review hours saved, as documented on the Alnylam ZENITH trial.
Deploy HealthKey on a Phase 2/3 epilepsy protocol that had stalled at two enrolled patients.
Outcome: 996,044 records processed, 39 eligible patients from 5,608 screened, and one patient found that another screening platform had missed.
Use Cases
- Prescreen 80,000 patient records daily for a Phase 3 trial and get a qualified list in days.
- Encode 42 strict eligibility criteria and surface matched patients in 11 days, beating enrollment targets.
- Screen 4.6M records across 6 sites to identify 23 eligible patients for a GLP-1 add-on trial.
- Replace manual chart reviews with automated daily patient lists, freeing CRCs for enrollment.
- Ramp up patient identification for a closing trial and fill slots within weeks, as with the J&J bladder cancer trial.
- Scale patient screening across multiple clinic locations without additional staffing.
- Find patients missed by other screening platforms, as on the Access CCT epilepsy trial.
- Cut manual chart-review hours on large cardiovascular protocols (1,280 hours saved on ZENITH).
Limitations
- The offer waiving implementation, protocol setup for five trials, and premium support fees is valid only through July 31, 2026.
- New sites are capped at 20 per quarter, so onboarding timing depends on availability.
- The platform depends on an EHR connection, so sites without an integrable EHR are out of scope.
- Documented results concentrate in obesity, epilepsy, cardiovascular, urology, and oncology — other therapeutic areas aren't backed by published case studies.
as of 2026-10-07
Verification history
We have re-verified HealthKey 9 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 9 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where HealthKey's pricing actually pencils out — and where peers do it cheaper.
HealthKey's success-fee model sits differently from seat- or license-priced patient-ID tools: you pay per enrolled patient, so cost tracks enrollment rather than headcount. Multi-site groups screening millions of records get the most leverage from that structure, while small sites with a handful of eligible patients see limited benefit. The current offer waiving $22,500 in implementation, protocol setup, and support fees makes the first studies materially cheaper through July 31, 2026.
Setup time & first value
How long it actually takes to get something useful out of HealthKey — broken out by persona, not the marketing-page minute.
HealthKey advertises getting started in one week — connect the EHR, encode the protocol criteria, and review matched candidates in days. EHR integration is the variable step, and new-site onboarding is capped at 20 sites per quarter, so the queue rather than the technical work is the usual source of delay.
Switching to or from HealthKey
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual chart review: connect the EHR, encode protocol criteria, and receive daily eligible-patient lists with chart evidence.
- →From another patient-identification platform: HealthKey's Access CCT epilepsy case found a patient missed by a competing screening tool.
- →From spreadsheet-based prescreening: replace manual record-by-record checks with automated daily EHR scans across multiple sites.
- ↗To manual chart review: export your matched candidate lists and continue screening in-house, at the cost of the review hours HealthKey was absorbing.
- ↗To a general-purpose trial management platform: move enrollment tracking there, but you lose HealthKey's daily EHR prescreening and chart-evidence matches.
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “HealthKey”, and we withheld 6: 6 could not be judged, because “HealthKey” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about HealthKey.
Official links
Tools that pair well with HealthKey
Common stack mates teams adopt alongside HealthKey, with the specific reason each pairing earns its keep.
Owkin
Owkin's K Pro is an autonomous AI scientist agent that informs biopharma R&D, clinical trial and portfolio decisions.
Insilico Medicine
Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.
Deep 6 AI
Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.
Featured Head-to-Head Comparisons
Healthkey vs Isomorphic Labs
These are not competitors and you will never pick one over the other. If you run a research site and need eligible patients in your EHR surfaced this week, HealthKey is the buy — one-week onboarding, free setup, success-fee pricing, and documented wins like 4,269 patients screened against 24 criteria at Flourish Research. If you are a large pharma with a target and a multi-year budget, Isomorphic Labs is a partner, not a product: Drug Design Engine collaborations running target identification through lead optimization, now including a Johnson & Johnson multi-target deal. Paying only for enrollments versus funding an R&D program are different decisions at different scales.
Healthkey vs Rapidsos
RapidSOS and HealthKey serve entirely different domains and buyer personas. RapidSOS is the go-to for public safety agencies needing AI-enhanced emergency response and connected device data, with recent network integration strengthening its 911 ecosystem. HealthKey is ideal for clinical research entities aiming to accelerate trial enrollment via AI-driven EHR scanning, with a risk-free pricing model. Choose based on your industry: emergency management vs. clinical research.
Healthkey vs Codametrix
For clinical trial recruitment with risk-free pricing, HealthKey is your tool—it scans EHRs daily to find candidates and charges only on success. But if you run a large health system drowning in coding costs and denials, CodaMetrix delivers proven 5:1 ROI and just won #1 Best in KLAS. They solve completely different problems; pick based on your department: research vs. revenue cycle.
Alternatives to HealthKey
View all
Owkin
Owkin's K Pro is an autonomous AI scientist agent that informs biopharma R&D, clinical trial and portfolio decisions.
Insilico Medicine
Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.
Frequently Asked Questions
Used HealthKey? Help shape our editorial sentiment research.